TNDM Stock Overview
Designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Tandem Diabetes Care, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.06 |
| 52 Week High | US$53.69 |
| 52 Week Low | US$15.75 |
| Beta | 1.53 |
| 1 Month Change | -11.01% |
| 3 Month Change | -52.89% |
| 1 Year Change | -49.07% |
| 3 Year Change | -85.21% |
| 5 Year Change | -76.61% |
| Change since IPO | -91.14% |
Recent News & Updates
FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes
Mar 22 Operational improvements and new tech launches are expected to boost customer adoption and revenue, with increased market presence and margin expansion initiatives in Europe.Not Many Are Piling Into Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Yet As It Plummets 40%
Feb 28
Recent updates
FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes
Mar 22 Operational improvements and new tech launches are expected to boost customer adoption and revenue, with increased market presence and margin expansion initiatives in Europe.Not Many Are Piling Into Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Yet As It Plummets 40%
Feb 28Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's Skepticism
Feb 27Is There An Opportunity With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 47% Undervaluation?
Jan 18Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?
Dec 27Tandem Diabetes: Recurring Value Erosion, Not Right Point In Cycle To Own
Nov 28Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch
Nov 16Health Check: How Prudently Does Tandem Diabetes Care (NASDAQ:TNDM) Use Debt?
Sep 28Potential Upside For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Not Without Risk
Aug 31Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin
Aug 14Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 04Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
Jul 12Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?
Jun 18Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here
May 29Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors
May 10A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
May 04At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?
Mar 26Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely
Mar 08Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?
Feb 22Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Jan 14Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company
Dec 27Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
Nov 12Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price
Oct 06Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?
Sep 17Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?
Aug 08Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
Jul 03Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?
Jun 13Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely
May 06Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?
Jan 04Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Potentially Undervalued?
Oct 15Tandem Diabetes Care: Overpriced, Underdelivering
Sep 22An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 50% Undervalued
Sep 10Tandem Diabetes stock falls 10% on disappointing Q2 result
Aug 03Shareholder Returns
| TNDM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.1% | 2.6% | 5.4% |
| 1Y | -49.1% | 1.0% | 3.6% |
Return vs Industry: TNDM underperformed the US Medical Equipment industry which returned 1% over the past year.
Return vs Market: TNDM underperformed the US Market which returned 3.6% over the past year.
Price Volatility
| TNDM volatility | |
|---|---|
| TNDM Average Weekly Movement | 11.9% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: TNDM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TNDM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 2,650 | John Sheridan | www.tandemdiabetes.com |
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body.
Tandem Diabetes Care, Inc. Fundamentals Summary
| TNDM fundamental statistics | |
|---|---|
| Market cap | US$1.13b |
| Earnings (TTM) | -US$96.02m |
| Revenue (TTM) | US$940.20m |
1.2x
P/S Ratio-11.8x
P/E RatioIs TNDM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNDM income statement (TTM) | |
|---|---|
| Revenue | US$940.20m |
| Cost of Revenue | US$450.63m |
| Gross Profit | US$489.57m |
| Other Expenses | US$585.60m |
| Earnings | -US$96.02m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 30, 2025
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 52.07% |
| Net Profit Margin | -10.21% |
| Debt/Equity Ratio | 134.5% |
How did TNDM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 15:43 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tandem Diabetes Care, Inc. is covered by 38 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | Barclays |
| Matthew Miksic | Barclays |